VirxSys Lentivirus IND For HIV Will Be Filed By First Quarter of 2002
Executive Summary
VirxSys is planning to submit an investigational new drug application for its HIV-1 lentiviral vector for treatment of patients infected with HIV by the first quarter of 2002
You may also be interested in...
Gene Therapy With Lentivirus Is Acceptable For Clinical Trials, ICH Panel Says
Lentiviral vectors are acceptable for use in human clinical trials but the safety studies required will depend on the patient population and disease indication under study, an International Conference on Harmonization workgroup said Sept. 9 during a gene therapy workshop in Vienna, Va
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011